Business Description
Metagenomi Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US59102M1045
Total Employee Number:
118Description
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.58 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -0.44 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -2.48 | |||||
Beneish M-Score | -3.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | -25.4 | |||||
3-Year EPS without NRI Growth Rate | -16.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.86 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.36 | |||||
9-Day RSI | 56.28 | |||||
14-Day RSI | 51.36 | |||||
3-1 Month Momentum % | -1.48 | |||||
6-1 Month Momentum % | -20.36 | |||||
12-1 Month Momentum % | -17.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.43 | |||||
Quick Ratio | 6.43 | |||||
Cash Ratio | 6.23 | |||||
Days Sales Outstanding | 14.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 10.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -415.48 | |||||
Net Margin % | -384.61 | |||||
EBITDA Margin % | -398.02 | |||||
FCF Margin % | -391.99 | |||||
OCF Margin % | -390.6 | |||||
ROE % | -48.62 | |||||
ROA % | -34.74 | |||||
ROIC % | -111.45 | |||||
3-Year ROIIC % | 385.12 | |||||
ROC (Joel Greenblatt) % | -185.71 | |||||
ROCE % | -42.64 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.11 | |||||
PB Ratio | 0.34 | |||||
Price-to-Tangible-Book | 0.34 | |||||
EV-to-EBIT | 0.58 | |||||
EV-to-EBITDA | 0.6 | |||||
EV-to-Revenue | -2.4 | |||||
EV-to-Forward-Revenue | 11.52 | |||||
EV-to-FCF | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 0.56 | |||||
| Price-to-Net-Cash | 0.59 | |||||
Earnings Yield (Greenblatt) % | 172.41 | |||||
FCF Yield % | -184.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Metagenomi Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 22.331 | ||
| EPS (TTM) ($) | -2.3 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 83.41 | ||
| 14-Day RSI | 51.36 | ||
| 14-Day ATR ($) | 0.071984 | ||
| 20-Day SMA ($) | 1.2215 | ||
| 12-1 Month Momentum % | -17.39 | ||
| 52-Week Range ($) | 1.13 - 3.95 | ||
| Shares Outstanding (Mil) | 37.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Metagenomi Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Metagenomi Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 40 days | ||
| General meeting for 2026 | 2026-06-09 08:00 | 1.29 (-0.77%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 07:35 | 1.33 (-0.75%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.41 (-1.40%) | ||
| Annual report for 2025 | 2026-03-05 | 1.60 (+5.26%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 1.60 (+5.26%) | ||
| the 46(th) Annual TD Cowen Healthcare Conference | 2026-03-02 11:10 | 1.52 (-3.18%) | ||
| Jefferies Global Healthcare Conference | 2025-11-20 04:30 | 1.61 (-4.73%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.20 (+2.33%) |
Show
Entries
Metagenomi Therapeutics Inc Frequently Asked Questions
What is Metagenomi Therapeutics Inc(MGX)'s stock price today?
The current price of MGX is $1.26. The 52 week high of MGX is $3.95 and 52 week low is $1.13.
When is next earnings date of Metagenomi Therapeutics Inc(MGX)?
The next earnings date of Metagenomi Therapeutics Inc(MGX) is 2026-08-12 Est..
Does Metagenomi Therapeutics Inc(MGX) pay dividends? If so, how much?
Metagenomi Therapeutics Inc(MGX) does not pay dividend.
Guru Commentaries on NAS:MGX
No articles.
Press Release
Articles on Metagenomi Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers